[625,000% Gain] – Are You Ready for the Next Altcoin Boom?

All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.

Joseph L. Goldstein net worth and biography

Joseph Goldstein Biography and Net Worth

Director of Regeneron Pharmaceuticals

Joseph L. Goldstein, MD, has been a Director of the Company since June 1991. Dr. Goldstein has been Professor of Medicine and Genetics and Chairman of the Department of Molecular Genetics at The University of Texas Southwestern Medical Center at Dallas since 1977. Dr. Goldstein is a member of the National Academy of Sciences. Drs. Goldstein and Brown jointly received the Nobel Prize for Physiology or Medicine in 1985.

What is Joseph L. Goldstein's net worth?: The estimated net worth of Joseph L. Goldstein is at least $4.74 million as of January 23rd, 2024. Dr. Goldstein owns 6,382 shares of Regeneron Pharmaceuticals stock worth more than $4,744,060 as of November 21st. This net worth evaluation does not reflect any other investments that Dr. Goldstein may own. Learn More about Joseph L. Goldstein's net worth.
How do I contact Joseph L. Goldstein?: The corporate mailing address for Dr. Goldstein and other Regeneron Pharmaceuticals executives is 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY, 10591. Regeneron Pharmaceuticals can also be reached via phone at (914) 847-7000 and via email at [email protected]. Learn More on Joseph L. Goldstein's contact information.
Has Joseph L. Goldstein been buying or selling shares of Regeneron Pharmaceuticals?: Joseph L. Goldstein has not been actively trading shares of Regeneron Pharmaceuticals during the last ninety days. Most recently, Joseph L. Goldstein sold 2,707 shares of the business's stock in a transaction on Tuesday, January 23rd. The shares were sold at an average price of $950.00, for a transaction totalling $2,571,650.00. Following the completion of the sale, the director now directly owns 6,382 shares of the company's stock, valued at $6,062,900. Learn More on Joseph L. Goldstein's trading history.
Who are Regeneron Pharmaceuticals' active insiders?: Regeneron Pharmaceuticals' insider roster includes Bonnie Bassler (Director), Michael Brown (Director), N. Coles (Director), Christopher Fenimore (VP), Joseph Goldstein (Director), Robert Landry (CFO), Joseph Larosa (EVP), Marion Mccourt (EVP), Andrew Murphy (EVP), Christine Poon (Director), Arthur Ryan (Director), Leonard Schleifer (CEO), George Sing (Director), Neil Stahl (EVP), Marc Tessier-Lavigne (Director), P. Vagelos (Director), Daniel Van Plew (EVP), George Yancopoulos (Insider), and Huda Zoghbi (Director). Learn More on Regeneron Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Regeneron Pharmaceuticals?: In the last year, insiders at the biopharmaceutical company sold shares 28 times. They sold a total of 108,095 shares worth more than $105,638,222.64. The most recent insider tranaction occured on August, 28th when CFO Christopher R Fenimore sold 5,680 shares worth more than $6,846,274.40. Insiders at Regeneron Pharmaceuticals own 7.5% of the company. Learn More about insider trades at Regeneron Pharmaceuticals.
Information on this page was last updated on 8/28/2024.

Joseph L. Goldstein Insider Trading History at Regeneron Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/23/2024	Sell	2,707	$950.00	$2,571,650.00	6,382
2/6/2023	Sell	3,613	$800.00	$2,890,400.00	6,247
9/10/2021	Sell	2,479	$650.00	$1,611,350.00	8,370
10/5/2020	Sell	9,212	$600.00	$5,527,200.00	14,855
9/22/2020	Sell	16,574	$549.87	$9,113,545.38
8/21/2020	Sell	1,000	$617.18	$617,180.00	111,632
6/8/2020	Sell	10,838	$608.59	$6,595,898.42
5/6/2020	Sell	2,000	$560.00	$1,120,000.00	7,643
11/27/2019	Sell	1,000	$370.00	$370,000.00	11,323
11/22/2019	Sell	1,000	$360.00	$360,000.00	11,323
11/8/2019	Sell	1,000	$340.44	$340,440.00	10,323
5/15/2019	Sell	1,000	$305.93	$305,930.00	11,323
1/10/2019	Sell	1,791	$410.00	$734,310.00	14,114
9/24/2018	Sell	2,000	$388.65	$777,300.00	13,000
8/2/2018	Sell	2,000	$380.00	$760,000.00	14,000
7/5/2018	Sell	2,000	$360.00	$720,000.00	14,000
3/19/2018	Sell	2,000	$350.02	$700,040.00	14,000
3/14/2018	Sell	2,000	$340.00	$680,000.00	14,000
2/9/2018	Sell	1,000	$325.60	$325,600.00
6/9/2017	Sell	1,000	$482.55	$482,550.00	14,000
11/14/2016	Sell	2,125	$450.00	$956,250.00	15,125
7/29/2016	Sell	2,125	$425.00	$903,125.00	15,125
4/6/2016	Sell	2,000	$425.00	$850,000.00	13,000
3/21/2016	Sell	2,000	$375.00	$750,000.00	16,000
7/15/2015	Sell	2,000	$550.00	$1,100,000.00
6/22/2015	Sell	2,000	$526.85	$1,053,700.00
5/22/2015	Sell	4,000	$514.28	$2,057,120.00
2/20/2015	Sell	5,000	$423.65	$2,118,250.00
11/12/2014	Sell	5,000	$398.31	$1,991,550.00
8/27/2014	Sell	2,000	$350.31	$700,620.00
8/14/2014	Sell	2,000	$347.65	$695,300.00
8/6/2014	Sell	2,000	$331.20	$662,400.00
5/28/2013	Sell	4,000	$252.20	$1,008,800.00

Joseph L. Goldstein Buying and Selling Activity at Regeneron Pharmaceuticals

Regeneron Pharmaceuticals Company Overview

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Today's Range

Now: $743.35

$736.01

$750.69

50 Day Range

MA: $961.76

$743.35

$1,164.46

2 Week Range

Now: $743.35

$736.01

$1,211.20

Volume

654,394 shs

Average Volume

860,893 shs

Market Capitalization

$81.69 billion

P/E Ratio

18.40

Dividend Yield

N/A

Beta

0.15